Discontinued — last reported Q4 '25
Eli Lilly Acquired in-process research and development increased by 10.4% to $584.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 62.8%, from $1.57B to $584.00M. Over 4 years (FY 2021 to FY 2025), Acquired in-process research and development shows an upward trend with a 31.6% CAGR.
High levels indicate an active inorganic growth strategy, while low levels suggest a focus on internal development.
This metric captures the costs associated with acquiring research and development projects from third parties that have...
Common in the pharmaceutical and biotech sectors where M&A is a primary strategy for pipeline replenishment.
lly_acquired_in_process_research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $42.80M | $177.60M | $437.70M | $165.60M | $440.40M | $62.40M | $240.10M | $105.00M | $97.10M | $2.98B | $622.80M | $110.50M | $154.30M | $2.83B | $188.80M | $1.57B | $153.80M | $655.70M | $528.80M | $584.00M |
| QoQ Change | — | +315.0% | +146.5% | -62.2% | +165.9% | -85.8% | +284.8% | -56.3% | -7.5% | >999% | -79.1% | -82.3% | +39.6% | >999% | -93.3% | +732.6% | -90.2% | +326.3% | -19.4% | +10.4% |
| YoY Change | — | — | — | — | +929.0% | -64.9% | -45.1% | -36.6% | -78.0% | >999% | +159.4% | +5.2% | +58.9% | -5.0% | -69.7% | >999% | -0.3% | -76.8% | +180.1% | -62.8% |
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Reportable Segment | $1.57B | $153.80M | $655.70M | $528.80M | $584.00M |
| Total | $1.57B | $153.80M | $655.70M | $528.80M | $584.00M |